Profile data is unavailable for this security.
About the company
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
- Revenue in HKD (TTM)11.07m
- Net income in HKD-283.69m
- Incorporated2014
- Employees219.00
- LocationAscletis Pharma Inc12F, Building D198 Qidi Road, HIPARKHANGZHOU ChinaCHN
- Websitehttps://www.ascletis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fusen Pharmaceutical Co Ltd | 467.01m | -98.42m | 709.73m | 1.14k | -- | 1.26 | -- | 1.52 | -0.132 | -0.132 | 0.6269 | 0.7617 | 0.3212 | 1.68 | 5.01 | 406,801.90 | -6.77 | 0.9678 | -13.96 | 1.74 | 53.18 | 51.95 | -21.08 | 2.59 | 0.526 | -2.10 | 0.4031 | 27.95 | 15.02 | 4.13 | -4.83 | -- | 0.2124 | -- |
| Pak Fah Yeow International Ltd | 265.21m | 96.45m | 763.52m | 101.00 | 7.92 | 1.02 | 7.36 | 2.88 | 0.3094 | 0.3094 | 0.8507 | 2.41 | 0.2869 | 2.84 | 23.53 | 2,600,118.00 | 10.44 | 3.99 | 11.32 | 4.18 | 87.05 | 80.79 | 36.37 | 21.27 | 4.22 | 5.26 | 0.0055 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
| Lee's Pharmaceutical Holdings Ltd | 1.20bn | 63.06m | 765.49m | 993.00 | 12.14 | 0.4467 | 3.90 | 0.6384 | 0.1071 | 0.1071 | 2.04 | 2.91 | 0.4403 | 2.11 | 9.70 | 1,134,410.00 | 1.98 | 13.33 | 2.52 | 17.76 | 51.49 | 61.92 | 4.50 | 36.20 | 0.7425 | 6.58 | 0.132 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
| 3D Medicines Inc | 536.51m | -493.60m | 774.62m | 193.00 | -- | 0.8324 | -- | 1.44 | -2.10 | -2.10 | 2.25 | 3.60 | 0.3746 | 4.94 | 5.79 | 2,709,658.00 | -37.27 | -- | -50.88 | -- | 91.97 | -- | -99.50 | -- | 2.56 | -- | 0.2517 | -- | 11.91 | -- | 48.78 | -- | -- | -- |
| Jbm (Healthcare) Ltd | 648.42m | 130.46m | 789.12m | 279.00 | 6.49 | 0.8221 | 4.29 | 1.22 | 0.1479 | 0.1479 | 0.7338 | 1.17 | 0.4645 | 4.25 | 5.98 | 2,324,068.00 | 9.83 | 4.38 | 12.04 | 5.52 | 52.14 | 46.47 | 21.16 | 12.69 | 1.25 | 89.68 | 0.1155 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 920.86m | 188.39m | 806.76m | 678.00 | 4.28 | 0.4639 | 6.38 | 0.8761 | 0.3363 | 0.3363 | 1.64 | 3.10 | 0.3574 | 2.10 | 2.94 | 1,085,925.00 | 7.31 | 7.67 | 10.25 | 10.48 | 75.46 | 78.79 | 20.46 | 20.68 | 1.62 | -- | 0.0502 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
| Zhaoke Ophthalmology Ltd | 62.80m | -249.22m | 824.67m | 297.00 | -- | 0.3696 | -- | 13.13 | -0.4575 | -0.4575 | 0.1152 | 4.09 | 0.0233 | 1.25 | 16.09 | 200,631.00 | -9.23 | -- | -10.51 | -- | 82.03 | -- | -396.86 | -- | 5.48 | -24.02 | 0.1114 | -- | -- | -- | 5.47 | -- | -- | -- |
| Zhongzhi Pharmaceutical Holdings Ltd | 2.24bn | 122.18m | 846.33m | 2.74k | 6.79 | 0.6967 | 3.58 | 0.3773 | 0.1443 | 0.1443 | 2.65 | 1.41 | 1.09 | 2.68 | 7.39 | 848,783.80 | 5.99 | 7.69 | 9.17 | 11.75 | 57.55 | 60.44 | 5.49 | 6.73 | 0.9033 | 213.59 | 0.1516 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | 3.22 |
| Hbm Holdings Ltd | 561.11m | 165.51m | 1.02bn | 158.00 | 5.91 | 1.02 | 5.21 | 1.82 | 0.225 | 0.225 | 0.7611 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,170,091.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
| Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.26bn | 1.72k | 5.76 | 0.5259 | 3.58 | 0.8585 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| Ascletis Pharma Inc | 11.07m | -283.69m | 1.33bn | 219.00 | -- | 0.5713 | -- | 120.41 | -0.2733 | -0.2733 | 0.0107 | 2.36 | 0.0041 | 1.34 | 3.58 | 50,568.44 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| SinoMab Bioscience Ltd | 2.22m | -219.12m | 1.50bn | 214.00 | -- | 4.92 | -- | 672.63 | -0.2103 | -0.2103 | 0.0021 | 0.2784 | 0.0023 | -- | -- | 10,342.69 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.65bn | 1.46k | 6.45 | 0.8166 | 5.18 | 1.02 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.18bn | 618.05m | 1.86bn | 1.18k | 3.01 | 0.5187 | 2.67 | 1.57 | 0.4114 | 0.4114 | 0.7882 | 2.39 | 0.2838 | 2.05 | 6.17 | 1,035,799.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| Cryofocus Medtech Shanghai Co Ltd | 45.56m | -116.62m | 1.91bn | 370.00 | -- | 14.77 | -- | 41.93 | -0.4877 | -0.4877 | 0.1906 | 0.5408 | 0.1881 | 0.418 | 4,369.58 | 116,227.70 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
Data as of Oct 10 2024. Currency figures normalised to Ascletis Pharma Inc's reporting currency: Hong Kong Dollar HKD
1.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 7.89m | 0.78% |
| Dimensional Fund Advisors LPas of 30 Apr 2024 | 3.68m | 0.36% |
| JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 2023 | 2.75m | 0.27% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.82m | 0.18% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.59m | 0.16% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 500.00k | 0.05% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 251.15k | 0.03% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 190.00k | 0.02% |
| American Century Investment Management, Inc.as of 03 Jul 2024 | 186.00k | 0.02% |
| The Vanguard Group, Inc.as of 31 Jan 2023 | 27.98k | 0.00% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
